Encompass Health (NYSE:EHC – Get Free Report) updated its FY24 earnings guidance on Monday. The company provided earnings per share guidance of $4.19-$4.33 for the period, compared to the consensus earnings per share estimate of $4.19. The company issued revenue guidance of $5.325-$5.375 billion, compared to the consensus revenue estimate of $5.32 billion. Encompass Health also updated its FY 2024 guidance to 4.190-4.330 EPS.
Encompass Health Stock Down 0.8 %
Shares of NYSE EHC traded down $0.84 during mid-day trading on Thursday, reaching $100.50. 431,941 shares of the company were exchanged, compared to its average volume of 637,958. The firm has a 50-day moving average of $94.14 and a 200 day moving average of $88.61. Encompass Health has a 1 year low of $61.08 and a 1 year high of $102.36. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 1.08. The stock has a market cap of $10.11 billion, a price-to-earnings ratio of 24.24, a P/E/G ratio of 1.45 and a beta of 0.88.
Encompass Health (NYSE:EHC – Get Free Report) last released its quarterly earnings results on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.09. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. Encompass Health had a net margin of 7.88% and a return on equity of 17.83%. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.86 earnings per share. On average, research analysts expect that Encompass Health will post 4.18 earnings per share for the current year.
Encompass Health Announces Dividend
Encompass Health announced that its board has approved a stock repurchase plan on Wednesday, July 24th that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 5.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.
Analyst Upgrades and Downgrades
EHC has been the subject of several recent research reports. Stephens reissued an “overweight” rating and set a $105.00 target price on shares of Encompass Health in a report on Tuesday, August 6th. Leerink Partners started coverage on Encompass Health in a report on Wednesday, July 10th. They set an “outperform” rating and a $100.00 target price on the stock. Leerink Partnrs raised shares of Encompass Health to a “strong-buy” rating in a research note on Wednesday, July 10th. Royal Bank of Canada increased their price target on shares of Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, KeyCorp increased their target price on shares of Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research note on Tuesday. Nine research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Encompass Health currently has an average rating of “Buy” and an average price target of $107.11.
View Our Latest Analysis on EHC
Insider Activity
In other Encompass Health news, CFO Douglas E. Coltharp sold 12,260 shares of Encompass Health stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total value of $1,058,528.40. Following the sale, the chief financial officer now owns 136,227 shares in the company, valued at $11,761,839.18. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.10% of the company’s stock.
About Encompass Health
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
See Also
- Five stocks we like better than Encompass Health
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- What is a SEC Filing?
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.